Physician profile
Thomas C Mcgee
NPI 1942253737
$11,885.53
in general payments reported to CMS, 2019-2025
39 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $1,192 · 2021: $2,134 · 2022: $1,964 · 2023: $1,894 · 2024: $1,900 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,408.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,259.14 | 2019-2025 | |
| Amgen INC. | $2,962.16 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Glaxosmithkline, LLC. | $1,275.03 | 2019-2025 | Benlysta, Bexsero, Pediarix |
| Janssen Biotech, INC. | $566.93 | 2019-2025 | Tremfya |
| Ucb, INC. | $403.11 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $378.25 | 2019-2023 | Jardiance, Emgality |
| Horizon Therapeutics Plc | $358.55 | 2019-2022 | |
| Pfizer INC. | $331.02 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $301.80 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $234.67 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $210.59 | 2021-2025 | Saphnelo, Farxiga |
| Genentech USA, INC. | $187.84 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $186.81 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $175.18 | 2020-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $136.20 | 2019-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.